EUVIMEDEUVIMED entdecken
LeserbriefFallbericht

Reversal of cystic bronchiectasis with elexacaftor/tezacaftor/ivacaftor

Peter G Middleton iD, Nicholas J Simmonds iD

European Respiratory Journal · 2024

DOI: 10.1183/13993003.00929-2024 ↗

Kurz gefasst

Leserbrief in der Zeitschrift European Respiratory Journal, 2024. Verfasst von Peter G Middleton und 1 weiteren Autor:innen. Beteiligte Einrichtung: Westmead Hospital, Ludwig Engel Centre for Respiratory Research, Sydney, Australia peter.middleton@sydney.edu.au. Hauptthemen laut MEDLINE: Benzodioxoles, Aminophenols, Indoles, Bronchiectasis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 3 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Extract The recent introduction of elexacaftor/tezacaftor/ivacaftor (ETI) has revolutionised care for people with cystic fibrosis around the world [1]. We read with interest the recent French study of the effects of ETI on lung structural abnormalities measured by computed tomography after 12 months of therapy. The authors should be commended for this comprehensive, important study. They demonstrated changes in the measures of cylindrical bronchiectasis, including bronchial wall thickness and dilatation, in approximately 5% of their cohort. However, no change in varicose and cystic bronchiectasis was found [2].

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenzodioxolesAminophenolsIndolesBronchiectasisQuinolonesPyrazolesPyridinesHumansMaleFemaleDrug CombinationsCystic FibrosisPyrrolesMiddle AgedChloride Channel AgonistsTreatment OutcomeQuinolinesCystic Fibrosis Transmembrane Conductance RegulatorPyrrolidines

Substanzen

BenzodioxolesAminophenolsIndolesQuinolonesPyrazolesPyridineselexacaftorDrug CombinationsivacaftorPyrroles

Autor:innen und Institutionen

  • Westmead Hospital, Ludwig Engel Centre for Respiratory Research, Sydney, Australia peter.middleton@sydney.edu.au.
  • University of Sydney, Sydney, Australia.
  • Royal Brompton Hospital, Adult Cystic Fibrosis Centre, London, UK.

ORCID-Profile: Peter G Middleton, Nicholas J Simmonds

Zitieren

APA

Middleton, P. G., & Simmonds, N. J. (2024). Reversal of cystic bronchiectasis with elexacaftor/tezacaftor/ivacaftor. European Respiratory Journal. https://doi.org/10.1183/13993003.00929-2024

Vancouver

Middleton PG, Simmonds NJ. Reversal of cystic bronchiectasis with elexacaftor/tezacaftor/ivacaftor. European Respiratory Journal. 2024. doi:10.1183/13993003.00929-2024

BibTeX
@article{Middleton2024,
  author = {Middleton, Peter G and Simmonds, Nicholas J},
  title = {Reversal of cystic bronchiectasis with elexacaftor/tezacaftor/ivacaftor},
  journal = {European Respiratory Journal},
  year = {2024},
  doi = {10.1183/13993003.00929-2024}
}
Kostenlos starten →